# A Study Evaluating TRIV-509 in Atopic Dermatitis

> **NCT07167758** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Triveni Bio** · enrollment: 95 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** TRIV-509
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07167758
- **Lead sponsor:** Triveni Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-08-26
- **Primary completion:** 2026-10
- **Final completion:** 2027-06
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07167758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07167758, "A Study Evaluating TRIV-509 in Atopic Dermatitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07167758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*